Zoster vaccine recommendations: The importance of using a clinically valid correlate of protection

Vaccine

Volumn 29, Issue 20, 2011, Pages 3625-3627

  Oxman, Michael N ^a   Gershon, Anne A ^b   Poland, Gregory A ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; VARICELLA ZOSTER VACCINE;

DRUG INFORMATION; EDITORIAL; HERPES ZOSTER; INFECTION PREVENTION; PNEUMOCOCCAL INFECTION; PRESCRIPTION; PRIORITY JOURNAL; VACCINATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY FORMATION; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINATION;

EID: 79955098203     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.019     Document Type: Editorial

References (30)

1. Tseng H.F., Smith N., Sy L.S., Jacobsen S.J. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 2011, 29(20):3628-3632.
2. Centers for Disease Control and Prevention. Recommended adult immunization schedule - United States, 2011. MMWR 2011;60(4):1-4.
3. Zostavax. prescribing information [package insert]. 2009;Section 7.1; 6.
4. High KP. Overcoming barriers to adult immunization. J Am Osteopath Assoc 2009 Jun;109(6 Suppl 2):S25-8.
5. Lieu T.A., Ortega-Sanchez I., Ray G.T., et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008, 26(3):235-249.
6. Hurley LP, Lindley MC, Harpaz R, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med 2010 May 4;152(9):555-60.
7. Lu PJ, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60years and older, in the U.S., 2008. Am J Prev Med 2011 Feb;40(2):e1-6.
8. Zostavax prescribing information [package insert]. 2009;Section 14:9.
9. MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60years old. Hum Vaccine 2010 Nov 1;6(11):894-902.
10. Kroger A.T., Sumaya C.V., Pickering L.K., Atkinson W.L. General recommendations on immunization: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2011, 60(RR02):1-60.
11. Brunell PA, Ross A, Miller LH, Kuo B. Prevention of varicella by zoster immune globulin. N Engl J Med 1969 May 29;280(22):1191-4.
12. Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin. A further assessment. N Engl J Med 1974 Jan 31;290(5):243-5.
13. Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983 Apr;147(4):737-43.
14. Michalik DE, Steinberg SP, LaRussa PS, et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 2008 Apr 1;197(7):944-9.
15. Li S, Chan IS, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002 Apr;21(4):337-42.
16. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004 Feb;23(2):132-7.
17. Gershon AA, Steinberg SP, Gelb L, et al. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA 1984 Jul 20;252(3):355-62.
18. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007 Jun 22;56(RR-4):1-40.
19. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010 Jul 15;51(2):197-213.
20. Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980; 30(June):582-7.
21. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981 Apr;32(1):24-7.
22. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982 Feb;142(2):291-3.
23. Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 1987 Mar;7(2):174-8.
24. Hayward A, Levin M, Wolf W, Angelova G, Gilden D. Varicella-zoster virus-specific immunity after herpes zoster. J Infect Dis 1991 Apr;163(4):873-5.
25. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005 Jun 2;352(22):2266-7.
26. Gershon AA, Steinberg SP. Antibody responses to varicella-zoster virus and the role of antibody in host defense. Am J Med Sci 1981 Jul;282(1):12-7.
27. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008 Mar 15;197(6):825-35.
28. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002 Jul 4;347(1):26-34.
29. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 Jun 2;352(22):2271-84.
30. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009 Oct 1;200(7):1068-77.